BSX

Boston Scientific has corrected sharply due to EP and WATCHMAN slowdowns, but 74% of its portfolio continues healthy growth. Weakness in BSX's EP business appears addressable with new product launches like FARAWAVE Ultra and ICE, expected to drive recovery from 2H 2027 onward. Valuation is compelling: BSX trades at 15.27x forward earnings, a significant discount to peers and historical averages, despite resilient core businesses.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Boston Scientific has been heavily sold off, now trading at attractive valuations versus peers after multiple guidance cuts. Despite U.S. growth headwinds for WATCHMAN and electrophysiology, BSX delivered strong Q2 2026 results with 7.5% sales growth and 14.7% adjusted EPS growth. International markets are driving robust growth for BSX, with electrophysiology up 23.1% and WATCHMAN up 17.7% outside the U.S.

MARLBOROUGH, Mass., Aug. 10, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Wells Fargo's 21st Annual Healthcare Conference on Thursday, September 10, 2026.

Boston Scientific's 2026 guidance cut tests its recovery as WATCHMAN weakness, EP share losses and delayed margin gains push a broader rebound toward 2028.

Boston Scientific's cheaper valuation offers upside, but weaker guidance, share losses, higher debt and delayed catalysts favor patience.

Boston Scientific ( BSX ) manufactures medical devices and products used in various interventional medical specialties worldwide, including cardiovascular and surgical categories. On July 29, BSX reported revenue of $5.44 billion for their June quarter, up 7.5% over the same period last year.

ALAMEDA, Calif., July 30, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2026.

BSX faces WATCHMAN and EP pressures as management cuts outlook while highlighting cost savings and new product catalysts for future growth.

Boston Scientific retains my buy rating with a $66 price target, reflecting 44% upside if negative earnings revisions stabilize. BSX has reset expectations, slashing guidance and acknowledging competitive pressures, particularly in WATCHMAN and electrophysiology segments. Valuation is now attractive at 13.7x forward earnings, with further upside contingent on management halting guidance cuts and delivering execution consistency.